- Home
- UFI vs KPTI Comparison
UFI vs KPTI Comparison
Compare UFI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFI
- KPTI
- Stock Information
- Founded
- UFI 1969
- KPTI 2008
- Country
- UFI United States
- KPTI United States
- Employees
- UFI N/A
- KPTI N/A
- Industry
- UFI Textiles
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- UFI Consumer Discretionary
- KPTI Health Care
- Exchange
- UFI Nasdaq
- KPTI Nasdaq
- Market Cap
- UFI N/A
- KPTI 103.5M
- IPO Year
- UFI N/A
- KPTI 2013
- Fundamental
- Price
- UFI $5.52
- KPTI $0.64
- Analyst Decision
- UFI
- KPTI Strong Buy
- Analyst Count
- UFI 0
- KPTI 4
- Target Price
- UFI N/A
- KPTI $5.00
- AVG Volume (30 Days)
- UFI 53.5K
- KPTI 1.0M
- Earning Date
- UFI 01-29-2025
- KPTI 11-05-2024
- Dividend Yield
- UFI N/A
- KPTI N/A
- EPS Growth
- UFI N/A
- KPTI N/A
- EPS
- UFI N/A
- KPTI N/A
- Revenue
- UFI $590,737,000.00
- KPTI $148,442,000.00
- Revenue This Year
- UFI $11.45
- KPTI $6.67
- Revenue Next Year
- UFI $6.84
- KPTI $8.58
- P/E Ratio
- UFI N/A
- KPTI N/A
- Revenue Growth
- UFI 1.35
- KPTI 1.77
- 52 Week Low
- UFI $5.41
- KPTI $0.63
- 52 Week High
- UFI $7.91
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- UFI 38.91
- KPTI 25.28
- Support Level
- UFI $5.48
- KPTI $0.75
- Resistance Level
- UFI $5.65
- KPTI $0.83
- Average True Range (ATR)
- UFI 0.15
- KPTI 0.05
- MACD
- UFI 0.04
- KPTI -0.01
- Stochastic Oscillator
- UFI 32.14
- KPTI 4.21
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.